Key result
Novel therapeutic approaches targeting defective calcium release via cardiac ryanodine receptors are currently being evaluated for arrhythmias in heart failure and CPVT.
Population
Patients with heart failure and inherited arrhythmia syndromes, such as catecholaminergic polymorphic…
Design
Review
Authors
Loading...
RyR2 leak drives arrhythmias in HF and CPVT; leaves open whether targeted stabilization improves clinical outcomes.
This review highlights the potential of targeting cardiac ryanodine receptors (RyR2) to correct defective calcium release and treat arrhythmias in heart failure and CPVT.
Wehrens et al. (2005) conducted a review in Heart failure and inherited arrhythmia syndromes (e.g., CPVT). Ryanodine Receptor-Targeted Anti-Arrhythmic Therapy was evaluated. Novel therapeutic approaches targeting defective calcium release via cardiac ryanodine receptors are currently being evaluated for arrhythmias in heart failure and CPVT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: